Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 3/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.49 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31599176 | 0.90 | LMNA (0.88) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2999532 | 0.87 | LMNA (0.77) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1200720 | 0.85 | LMNA (0.74) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31241187 | 0.85 | LMNA (0.92) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8393465 | 0.84 | LMNA (0.73) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| Benzene SCHEMBL27888748 | 0.84 | LMNA (1.00) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL95238 | 0.84 | LMNA (1.00) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29361707 | 0.84 | LMNA (1.00) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23036030 | 0.83 | LMNA (0.75) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1201051 | 0.83 | LMNA (0.75) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119192126-A | Preparation method of oxygen/thioxanthone compound | 湖南科技大学 | 2024-12-27 | — | — | CN | disclosed |
| CN-119192125-A | Preparation method of oxygen/thioxanthene compound | 湖南科技大学 | 2024-12-27 | — | — | CN | disclosed |
| CN-110317200-B | Pyrimidinium compounds and uses thereof | 东莞市东阳光农药研发有限公司 | 2020-09-11 | — | — | CN | disclosed |
| CN-110317200-A | Pyrimidine compound and application thereof | 东莞东阳光科研发有限公司 | 2019-10-11 | — | — | CN | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| EP-2154123-B1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| WO-2013006596-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264005-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-7851659-B2 | Method for producing benzaldehyde compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20100234645-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2154123-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-02-17 | — | — | EP | disclosed |
| EP-0726265-B1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | NOVARTIS AG (CH) | 2001-07-25 | — | — | EP | disclosed |
| US-5780501-A | ADMINISTERING TO A MAMMAL | NOVARTIS CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| US-5780500-A | Anti-neurodegeneratively active 10-aminoaliphatyl-dibenzi b,f! oxepines | NOVARTIS CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0726265-A1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | CIBA-GEIGY AG (CH) | 1996-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | ALDH1A1 2656/4885LMNA 611/4885CYP1A2 1524/4885 |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | ALDH1A1 2495/4885LMNA 816/4885CYP1A2 1621/4885 |
| US-20100234645-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | NQO1, NQO2, NDUFC2 | ALDH1A1 94/4885LMNA 2113/4885CYP1A2 130/4885 |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | CBR3, ACSL3, CCNL2 | ALDH1A1 129/4885LMNA 441/4885CYP1A2 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.